World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 6 January 2025
Main ID:  NCT05116787
Date of registration: 02/11/2021
Prospective Registration: No
Primary sponsor: BioCryst Pharmaceuticals
Public title: BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy REDEEM-2
Scientific title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Date of first enrolment: October 26, 2021
Target sample size: 12
Recruitment status: Terminated
URL:  https://clinicaltrials.gov/ct2/show/NCT05116787
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).  
Phase:  Phase 2
Countries of recruitment
Korea, Republic of Malaysia South Africa Spain Taiwan United States
Contacts
Name:     David J Kuter, MD, DPhil
Address: 
Telephone:
Email:
Affiliation:  Massachusetts General Hospital
Key inclusion & exclusion criteria
Inclusion Criteria:

- Male or female, aged = 18 years old

- Body weight = 40 kg

- Documented diagnosis of PNH

- No complement inhibitor therapy for = 12 months prior to screening

- Contraindication to or no access to approved (C3 or C5) complement inhibitor
therapies

- Documentation of current vaccinations against Neisseria meningitidis and
Streptococcus pneumoniae or willingness to start vaccination series

- At screening: PNH clone of = 10%, hemoglobin = 10.5 g/dL and lactate dehydrogenase =
2 × upper limit of normal

Exclusion Criteria:

- Known history of or existing diagnosis of hereditary complement deficiency

- History of hematopoietic cell transplant or solid organ transplant or anticipated
candidate for transplantation

- Myocardial infarction or cerebrovascular accident within 30 days prior to screening,
or current and uncontrolled clinically significant cardiovascular or cerebrovascular
condition

- History of malignancy within 5 years prior to the screening visit

- Active bacterial, viral, or fungal infection or any other serious infection within
14 days prior to screening

- Treatment with anti-thymocyte globulin within 180 days prior to screening

- Initiation of treatment with an erythrocyte or platelet growth factor, or danazol
within 28 days prior to screening

- Receiving iron supplementation with an unstable dose in the 28 days prior to
screening



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention(s)
Drug: BCX9930 monotherapy
Drug: Placebo
Primary Outcome(s)
Part 1: Change From Baseline in Hemoglobin at Week 12 [Time Frame: Baseline, Week 12]
Secondary Outcome(s)
Part 1: Change From Baseline in Aspartate Aminotransferase (AST) [Time Frame: Baseline, Week 12]
Part 1: Change From Baseline in Absolute Reticulocyte Count (ARC) [Time Frame: Baseline, Week 12]
Part 1: Change From Baseline in Haptoglobin [Time Frame: Baseline, Week 12]
Part 1: Number of Participants Who Were Transfusion-free [Time Frame: From Week 4 to Week 12]
Part 1: Number of Participants With ARC in the Normal Range [Time Frame: Week 12]
Part 1: Percentage (%) Reduction in the Rate of pRBC Units Transfused [Time Frame: Prestudy (12 months prior to screening) and from Week 4 to Week 12]
Part 1: Change From Baseline in Ratio of Total PNH RBC Clone Size to PNH White Blood Cell (WBC) Clone Size [Time Frame: Baseline, Week 12]
Part 1: Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Score [Time Frame: Baseline, Week 12]
Part 1: Change From Baseline in Total Bilirubin [Time Frame: Baseline, Week 12]
Part 1: Number of Participants With Haptoglobin = Lower Limit of Normal (LLN) Reference Range [Time Frame: Week 12]
Part 1: Number of Units of pRBCs Transfused [Time Frame: From Week 4 to Week 12]
Part 1: Change From Baseline in Total Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell (RBC) Clone Size [Time Frame: Baseline, Week 12]
Part 1: Number of Participants Achieving Hemoglobin Stabilization [Time Frame: From Week 4 to Week 12]
Part 1: Percent Change From Baseline in Lactate Dehydrogenase [Time Frame: Baseline, Week 12]
Part 1: Number of Participants With Hemoglobin = 12 g/dL [Time Frame: At Week 12]
Secondary ID(s)
2020-004403-14
BCX9930-203
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 03/01/2025
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT05116787
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey